Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ian Haydock
The latest group of new product approvals in Japan includes the first marketing clearances worldwide for fracture-reducing osteoporosis antibody romosozumab, a stem cell-based therapy for spinal cord injury, two new Daiichi drugs, and Pfizer's lung cancer therapy dacomitinib.
In an exclusive interview, Japanese tech giant NEC tells Scrip it is aiming for much more than the provision of IT tools in its AI-assisted Drug Discovery Initiative, hoping also to progress assets deriving from cutting-edge technology research.
With the formal completion of its huge acquisition of Shire now just a day away, some eight months after it was first announced, Takeda CEO presses home what he sees as the key priorities and benefits of the combined operation - but the real work to realize these is just beginning.
In moves aimed at boosting its presence in the immuno-oncology field, Takeda unveils a series of new research collaborations it believes will lead to pipeline gains in this critical field over the next few years.
2018 in Japan wasn't all about Takeda and Shire - though it mostly was. Amid a generally quiet year for M&A otherwise, companies concentrated on honing their specialty focus, dealing with major patent expiries, and fretting about big changes to the country's pricing system.